PMID- 17181558
OWN - NLM
STAT- MEDLINE
DCOM- 20070320
LR  - 20131121
IS  - 0022-3042 (Print)
IS  - 0022-3042 (Linking)
VI  - 100
IP  - 3
DP  - 2007 Feb
TI  - In vivo analysis of serotonin clearance in rat hippocampus reveals that repeated 
      administration of p-methoxyamphetamine (PMA), but not 
      3,4-methylenedioxymethamphetamine (MDMA), leads to long-lasting deficits in 
      serotonin transporter function.
PG  - 617-27
AB  - p-Methoxyamphetamine (PMA) has been implicated in fatalities as a result of 
      'ecstasy' (MDMA) overdose worldwide. Like MDMA, acute effects are associated with 
      marked changes in serotonergic neurotransmission, but the long-term effects of 
      PMA are poorly understood. The aim of this study was to determine the effect of 
      repeated PMA administration on in vitro measures of neurodegeneration: serotonin 
      (5-HT) uptake, 5-HT transporter (SERT) density and 5-HT content in the 
      hippocampus, and compare with effects on in vivo 5-HT clearance. Male rats 
      received PMA, MDMA (4 or 15 mg/kg s.c., twice daily) or vehicle for 4 days and 2 
      weeks later indices of SERT function were measured. [(3)H]5-HT uptake into 
      synaptosomes and [(3)H]cyanoimipramine binding to the SERT were significantly 
      reduced by both PMA and MDMA treatments. 5-HT content was reduced in MDMA-, but 
      not PMA-treatment. In contrast, clearance of locally applied 5-HT measured in 
      vivo by chronoamperometry was only reduced in rats treated with 15 mg/kg PMA. The 
      finding that 5-HT clearance in vivo was unaltered by MDMA treatment suggests that 
      in vitro measures of 5-HT axonal degeneration do not necessarily predict 
      potential compensatory mechanisms that maintain SERT function under basal 
      conditions.
FAU - Callaghan, Paul D
AU  - Callaghan PD
AD  - Department of Physiology, The University of Texas Health Science Center at San 
      Antonio, TX 78229-3900, USA.
FAU - Owens, W Anthony
AU  - Owens WA
FAU - Javors, Martin A
AU  - Javors MA
FAU - Sanchez, Teresa A
AU  - Sanchez TA
FAU - Jones, David J
AU  - Jones DJ
FAU - Irvine, Rodney J
AU  - Irvine RJ
FAU - Daws, Lynette C
AU  - Daws LC
LA  - eng
GR  - R01 MH64489/MH/NIMH NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20061201
PL  - England
TA  - J Neurochem
JT  - Journal of neurochemistry
JID - 2985190R
RN  - 0 (Amphetamines)
RN  - 0 (Serotonin Agents)
RN  - 0 (Serotonin Plasma Membrane Transport Proteins)
RN  - 333DO1RDJY (Serotonin)
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
RN  - OVB8F8P39Q (4-methoxyamphetamine)
SB  - IM
MH  - Amphetamines/*pharmacology
MH  - Animals
MH  - Binding, Competitive/drug effects/physiology
MH  - Hippocampus/*drug effects/metabolism/physiopathology
MH  - Male
MH  - Metabolic Clearance Rate/drug effects/physiology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*pharmacology
MH  - Presynaptic Terminals/drug effects/metabolism
MH  - Radioligand Assay
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Serotonin/*metabolism/pharmacokinetics
MH  - Serotonin Agents/pharmacology
MH  - Serotonin Plasma Membrane Transport Proteins/drug effects/*metabolism
MH  - Synaptosomes/chemistry/metabolism
MH  - Wallerian Degeneration/chemically induced/metabolism/physiopathology
EDAT- 2006/12/22 09:00
MHDA- 2007/03/21 09:00
CRDT- 2006/12/22 09:00
PHST- 2006/12/22 09:00 [pubmed]
PHST- 2007/03/21 09:00 [medline]
PHST- 2006/12/22 09:00 [entrez]
AID - JNC4247 [pii]
AID - 10.1111/j.1471-4159.2006.04247.x [doi]
PST - ppublish
SO  - J Neurochem. 2007 Feb;100(3):617-27. doi: 10.1111/j.1471-4159.2006.04247.x. Epub 
      2006 Dec 1.